‘It’s not a miracle drug’: Eli Lilly’s antibody slows Alzheimer’s disease but safety issues linger | Science
Clinical trial results released today by Eli Lilly and Co. indicate its antibody donanemab clearly, if perhaps modestly, slows the progression of Alzheimer’s disease. Following on the heels of comparable results for a similar antibody, lecanemab, the data bolster the long-held but contested hypothesis that preventing the accumulation of a protein called beta amyloid in the brain could help the many millions of people who develop the fatal neurodegenerative…